SCHEMBL528755

SCHEMBL528755

CC(C)CCN(C(=O)C1CCCCCC1)c1cc(Cl)c(Cl)cc1SC(=O)C(C)(C)C

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CETP P11597 8/20 0.47
▸ TDP1 Q9NUW8 1/20 0.39
▸ CNR2 P34972 2/20 0.33
▸ ITGB1 P05556 1/20 0.33
▸ ITGA4 P13612 1/20 0.33
▸ ACHE P22303 1/20 0.33
▸ LMNA P02545 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ TP53 P04637 1/20 0.32
▸ CNR1 P21554 1/20 0.31
▸ NR1H4 Q96RI1 1/20 0.31
▸ KDM4E B2RXH2 1/20 0.31
▸ APAF1 O14727 1/20 0.31
▸ TSHR P16473 1/20 0.31
▸ NPSR1 Q6W5P4 1/20 0.31
▸ HSD17B10 Q99714 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL528752 1.00 CETP (0.47) CETPTDP1CNR2ITGB1ITGA4
SCHEMBL529211 0.99 CETP (0.46) CETPTDP1CNR2ITGB1ITGA4
SCHEMBL529223 0.97 CETP (0.46) CETPTDP1ITGB1ITGA4ACHE
SCHEMBL528972 0.89 CETP (0.39) CETPTDP1ACHEALDH1A1NR1H4
SCHEMBL528722 0.88 CETP (0.48) CETPTDP1CNR2ACHEALDH1A1
SCHEMBL528965 0.88 CETP (0.48) CETPTDP1CNR2ITGB1ITGA4
SCHEMBL527982 0.87 TDP1 (0.42) CETPTDP1CNR2ITGB1ITGA4
SCHEMBL528417 0.85 CNR2 (0.40) CETPCNR2ACHELMNASMN1; SMN2
SCHEMBL528727 0.85 CETP (0.46) CETPTDP1ACHESMN1; SMN2ALDH1A1
SCHEMBL528968 0.85 CETP (0.48) CETPTDP1ACHESMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3833336-A1 METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES DalCor Pharma UK Ltd Leatherhead, Zug Branch (CH) 2021-06-16 — — EP claimed
WO-2020030814-A1 METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) 2020-02-13 — — WO claimed
WO-2019043018-A1 METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS DALCOR PHARMA UK LTD., STOCKPORT ZUG BRANCH (CH) 2019-03-07 — — WO claimed
EP-1603553-A2 PHARMACEUTICAL COMPOSITIONS OF CETP INHIBITORS JAPAN TOBACCO INC. (JP) 2005-12-14 — — EP claimed
WO-2004082593-A2 PHARMACEUTICAL COMPOSITIONS OF CETP INHIBITORS JAPAN TOBACCO INC. (JP) 2004-09-30 — — WO claimed
EP-3833336-A1 METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES DalCor Pharma UK Ltd Leatherhead, Zug Branch (CH) 2021-06-16 — — EP disclosed
WO-2020030814-A1 METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) 2020-02-13 — — WO disclosed
WO-2019043018-A1 METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS DALCOR PHARMA UK LTD., STOCKPORT ZUG BRANCH (CH) 2019-03-07 — — WO disclosed
EP-2598158-A1 PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION COMPRISING AN APOLIPOPROTEIN PEPTIDE/PHOSPHOLIPID COMPLEX Institut de Cardiologie de Montréal (CA) 2013-06-05 — — EP disclosed
WO-2012012870-A1 PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION COMPRISING AN APOLIPOPROTEIN PEPTIDE/PHOSPHOLIPID COMPLEX INSTITUT DE CARDIOLOGIE DE MONTREAL (CA) 2012-02-02 — — WO disclosed
EP-1603553-A2 PHARMACEUTICAL COMPOSITIONS OF CETP INHIBITORS JAPAN TOBACCO INC. (JP) 2005-12-14 — — EP disclosed
WO-2004082593-A2 PHARMACEUTICAL COMPOSITIONS OF CETP INHIBITORS JAPAN TOBACCO INC. (JP) 2004-09-30 — — WO disclosed
Send feedback